GlassScriptPhysician profile
Bryan Paul Crenshaw
NPI 1669634796
$5,739.71
in general payments reported to CMS, 2019-2025
40 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $641 · 2021: $855 · 2022: $538 · 2023: $519 · 2024: $982 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,813.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,336.32 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $902.45 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $354.09 | 2019-2025 | |
| Amgen INC. | $334.50 | 2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $269.54 | 2019-2024 | Breztri |
| Novartis Pharmaceuticals Corporation | $253.09 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $225.51 | 2023-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $205.41 | 2019-2022 | |
| Lilly USA, LLC | $191.99 | 2019-2023 | Mounjaro |
| Organogenesis INC. | $184.54 | 2024 | Affinity, Novachor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.30 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.74 | 2020-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $140.47 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $123.34 | 2025 | Cobenfy |
| Daiichi Sankyo INC. | $105.56 | 2019-2025 | Injectafer |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Crenshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.